top bottom line well estim full year revenu ep
ep estim consensu ep guidanc
rais prior includ slight neg fx impact
vs prior slight posit last publish ep estim
sale forecast
consensu product beat revenu forecast includ gardasil
keytruda zepati zetia combin
estim proquad/mmr ii/varivax vaccin sale
estim product forecast includ januvia isentress singulair
vytorin cubicin remicad simponi combin forecast
anim sale forecast full year revenu
guidanc rais prior includ fx impact vs
prior last publish revenu estim review
gpm estim
estim sg forecast net non-
op incom estim tax rate
forecast ad ep share count estim
oper expens guidanc updat increas mid singl digit vs prior increas
low mid singl digit due higher expect remaind guidanc
unchang
keytruda data sclc bladder cscc lynparza w/azn ph data
ovarian mainten mcrpc file pancreat cancer gefapix ph ii data
endometri pain vericiguat ph data hfeef complet list event shown
follow page
pleas see page report import disclosur
cowen compani
cowen compani compani data
cowen compani
cowen compani
cowen compani
m-m-r ii cowen
cowen compani
phase trial w/doravirin hivkeytrudaph data sclc w/chemoph ii data nmibc bladderph data bladderful ph data neoadjuvant/adjuv tnbc posit top-lin juli data tnbcph data msi-h stage iv crcph ii data cscclynparza w/azn ph data ovarian mainten w/avastin regardless brca statu data profound mcrpc ii data endometriosissteglatrophas verti cv cv outcom datavericiguatphas data hfref primari complet aug pifeltr label updat use switch patient pdufa vaccin file roll submiss keytrudaregulatori file esophag cancer file neo adjuv tnbc inlytaeu approv rcc posit chmp juli w/azn regulatori file pancreat cancer file brcam ovarian cancercn approv brcam ovarian cancer w/azn regulatori file neurofibromatosi type approv hap/vap posit chmp juli cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock merck secur
author report member author household long posit equiti secur merck
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
